Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?

Abstract

Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Baylin SB, Herman JG . 2000 Trends Genet. 16: 168–174

  • Borden KL . 1998 Biochem. Cell. Biol. 76: 351–358

  • Casini T, Pelicci PG . 1999 Oncogene 18: 3235–3243

  • Deininger MW, Goldman JM . 1998 Curr. Opin. Hematol. 5: 302–308

  • Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH . 2000 EMBO J. 19: 843–851

  • Ferrara F, Fazi F, Padula F, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C . 2001 Cancer Res in press

  • Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA . 1998 Mol. Cell. Biol. 18: 7185–7191

  • Glass CK, Rosenfeld MG . 2000 Genes Dev. 14: 121–141

  • Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG . 1998 Nature 391: 815–818

  • Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R . 2000 Genes Dev. 14: 1048–1057

  • Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A . 1998 Blood 91: 2634–2642

  • He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP . 1998 Nat. Genet. 18: 126–135

  • Hiebert SW, Downing JR, Lenny N, Meyers S . 1996 Curr. Top. Microbiol. Immunol. 211: 253–258

  • Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA . 2000 Genes Dev. 14: 45–54

  • Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J . 1997 EMBO J. 16: 69–82

  • Kastner P, Lawrence J, Waltzinger C, Ghyselinck N, Chambon P, Chan S . 2001 Blood in press

  • Kitabayashi I, Yokoyama A, Shimizu K, Ohki M . 1998 EMBO J. 17: 2994–3004

  • Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA . 1997 Science 278: 1309–1312

  • Lemon B, Tjian R . 2000 Genes Dev. 14: 2551–2569

  • Lin RJ, Evans RM . 2000 Mol. Cell 5: 821–830

  • Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM . 1998 Nature 391: 811–814

  • Liu M, Iavarone A, Freedman LP . 1996a J. Biol. Chem. 271: 31723–31728

  • Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP . 1996b Genes Dev. 10: 142–153

  • Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG . 1999 Blood 94: 12–22

  • Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW . 1998 Mol. Cell. Biol. 18: 7176–7184

  • Marks PA, Richon VM, Rifkind RA . 2000 J. Natl. Cancer Inst. 92: 1210–1216

  • Matsumura I, Ishikawa J, Nakajima K, Oritani K, Tomiyama Y, Miyagawa J, Kato T, Miyazaki H, Matsuzawa Y, Kanakura Y . 1997 Mol. Cell. Biol. 17: 2933–2943

  • Melnick A, Licht JD . 1999 Blood 93: 3167–3215

  • Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG . 2000 Mol. Cell 5: 811–820

  • Minucci S, Pelicci PG . 1999 Semin. Cell. Dev. Biol. 10: 215–225

  • Ng HH, Bird A . 2000 Trends Biochem. Sci. 25: 121–126

  • Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ . 1995 Science 267: 1024–1027

  • Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG . 2000 Nature 406: 207–210

  • Prowse DM, Bolgan L, Molnar A, Dotto GP . 1997 J. Biol. Chem. 272: 1308–1314

  • Ptashne M, Gann A . 1997 Nature 386: 569–577

  • Saurin AJ, Borden KL, Boddy MN, Freemont PS . 1996 Trends Biochem. Sci. 21: 208–214

  • Strahl BD, Allis CD . 2000 Nature 403: 41–45

  • Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD . 1999 Oncogene 18: 1015–1022

  • Val Lint C, Emiliani S, Verdin E . 1996 Gene Expr. 5: 245–253

  • Wang J, Saunthararajah Y, Redner RL, Liu JM . 1999 Cancer Res. 59: 2766–2769

  • Warrell Jr RP, He LZ, Richon V, Calleja E, Pandolfi PP . 1998 J. Natl. Cancer Inst. 90: 1621–1625

  • Westervelt P, Ley TJ . 1999 Blood 93: 2143–2148

  • Xu L, Glass CK, Rosenfeld MG . 1999 Curr. Opin. Genet. Dev. 9: 140–147

  • Zeng YX, el-Deiry WS . 1996 Oncogene 12: 1557–1564

  • Zeng YX, Somasundaram K, el-Deiry WS . 1997 Nat. Genet. 15: 78–82

  • Zhang J, Hug B, Huang E, Chen C, Gelmetti V, Maccarana M, Minucci S, Pelicci PG, Lazar MA . 2001 Mol. Cell. Biol. 21: 156–163

  • Zhong S, Salomoni P, Pandolfi PP . 2000 Nat. Cell. Biol. 2: E85–E90

Download references

Acknowledgements

We gratefully acknowledge Philippe Kastner for sharing results prior to publication, and people from our labs for useful discussions.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minucci, S., Nervi, C., Coco, F. et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 20, 3110–3115 (2001). https://doi.org/10.1038/sj.onc.1204336

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204336

Keywords

This article is cited by

Search

Quick links